NEW YORK--(BUSINESS WIRE)--Pluristem Life Systems, Inc. (OTCBB:PLRS), a cell therapy Company dedicated to the commercialization of cell therapy products for a variety of indications, has announced it will upgrade and enlarge its existing manufacturing facility to Support $200 Million in Production Capacity for PLX – I. The additional 6,900 square foot will double in size the Company’s facilities and is expected to be ready this summer. This facility will manufacture PLX-I, the Company’s introductory product to address the bone marrow transplant market, for Phase I clinical trials and large scale commercial production.
